Search

Search Constraints

You searched for: Author/Creator Kates, Ronald

Search Results

1. BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial. Issue 4 (5th May 2016)

2. Breast cancer surgery with augmented reality. (April 2021)

3. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Issue 5 (May 2022)

4. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial. Issue 1 (19th June 2019)

6. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. Issue 5 (7th May 2021)

9. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. (14th November 2021)